During his tenure, Merck gained approval of more than 20 new medicines and vaccines. These include Januvia (the first DPP-4 inhibitor for type 2 diabetes), Gardasil (the first vaccine for prevention of cervical cancer), Isentress (the first HIV integrase inhibitor), Zostavax (the first vaccine for the prevention of shingles in adults), Rotateq (an oral vaccine for the prevention of rotavirus infection in infants), and Victrelis (the first hepatitis C protease inhibitor). In 2013, he retired from Merck and was succeeded by Roger Perlmutter